5-(2-amino-5-chlorophenyl)-3-phenyl-1H-1,2,4-triazole | 104615-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(2-amino-5-chlorophenyl)-3-phenyl-1H-1,2,4-triazole
• 英文别名: 4-Chloro-2-(5-phenyl-2H-[1,2,4]triazol-3-yl)-phenylamine；4-chloro-2-(3-phenyl-1H-1,2,4-triazol-5-yl)aniline
• CAS: 104615-59-0
• 化学式: C₁₄H₁₁ClN₄
• 分子量: 270.721
• InChiKey: HVDNECJRVKOPKV-UHFFFAOYSA-N

物化性质

• 熔点：
  254-256 °C(Solv: toluene (108-88-3))
• 沸点：
  534.5±60.0 °C(Predicted)
• 密度：
  1.360±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(2-amino-5-chlorophenyl)-3-phenyl-1H-1,2,4-triazole 生成 9-chloro-2-phenyl<1,2,4>triazolo<1,5-c>quinazolin-5(6H)-one
  参考文献：
  名称：

  FRANCIS, JOHN E.;CASH, WILLIAM D.;BARBAZ, BEVERLY S.;BERNARD, PATRICK S.;+, J. MED. CHEM., 34,(1991) N, C. 281-290

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-5-氯苯腈 在 盐酸 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 9.0h， 生成 5-(2-amino-5-chlorophenyl)-3-phenyl-1H-1,2,4-triazole
  参考文献：
  名称：

  Gatta, Franco; Giudice, Del, Maria Rosaria; Borioni, Maria, Journal of Heterocyclic Chemistry, 1993, vol. 30, p. 11 - 16

  摘要：

  DOI：

文献信息

• Synthesis of Diverse Azolo[<i>c</i>]quinazolines by Palladium(II)- Catalyzed Aerobic Oxidative Insertion of Isocyanides
  作者：Tjøstil Vlaar、Lisa Bensch、Jasper Kraakman、Christophe M. L. Vande Velde、Bert U. W. Maes、Romano V. A. Orru、Eelco Ruijter

  DOI：10.1002/adsc.201301129

  日期：2014.4.14

  We report the palladium(II)‐catalyzed aerobic oxidative coupling of isocyanides with various (2‐aminophenyl)azoles using air as the stoichiometric oxidant. A diverse range of medicinally valuable azolo[c]quinazolines was obtained by this new approach.

  我们报告了使用空气作为化学计量氧化剂，钯（II）催化的异氰酸酯与各种（2-氨基苯基）唑类的好氧氧化偶联。通过这种新方法，获得了多种医学上有价值的氮杂[ c ]喹唑啉。
• Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives
  申请人：Knust Henner

  公开号：US20060079507A1

  公开（公告）日：2006-04-13

  The present invention is concerned with a method of treating a disease selected from the group consisting of cognitive disorders, anxiety, Alzheimer's disease, and schizophrenia comprising administering a therapeutically effective amount of a substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the following formula wherein R 1 is halogen, lower alkyl, lower alkynyl, cycloalkyl, lower alkoxy, OCF 3 , —NHR, —NHC(O)R or —NHSO 2 R; R 2 is hydrogen, methyl or aryl which is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen and lower alkoxy; R 3 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, lower alkoxy, —O(CH 2 ) n+1 —O-lower alkyl, —(CH 2 ) n -aryl which is optionally substituted by lower alkyl or halogen, heteroaryl, —NHR, —N(R) 2 , wherein each R can be the same or different, —NHCH 2 C≡CH, or pyrrolidin-1-one; R is hydrogen, lower alkyl, lower alkyl substituted by halogen, heteroaryl, —(CH 2 ) n O-lower alkyl, —NH-lower alkyl, cycloalkyl or aryl, and n is 0, 1, 2 or 3; and with their pharmaceutically acceptable acid addition salts. The invention also provides novel compounds of formula I-A and pharmaceutical compositions containing them. The most preferred indication is Alzheimer's disease.

  本发明涉及一种治疗从认知障碍、焦虑、阿尔茨海默病和精神分裂症中选择的疾病的方法，包括给予下列公式的取代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮䓬啉衍生物的治疗有效量：其中R1是卤素、较低烷基、较低炔基、环烷基、较低烷氧基、OCF3、—NHR、—NHC(O)R或—NHSO2R；R2是氢、甲基或芳基，未取代或由卤素和较低烷氧基中选择的一种或两种取代基取代；R3是氢、较低烷基、较低烯基、环烷基、较低烷氧基、—O(CH2)n+1—O-较低烷基、—(CH2)n-芳基，可由较低烷基或卤素取代，杂芳基、—NHR、—N(R)2，其中每个R可以相同也可以不同，—NHCH2C≡CH，或吡咯烷酮；R是氢、较低烷基、由卤素取代的较低烷基、杂芳基、—(CH2)nO-较低烷基、—NH-较低烷基、环烷基或芳基，n为0、1、2或3；以及其药学上可接受的酸盐。该发明还提供了公式I-A的新化合物和含有它们的药物组合物。最受欢迎的适应症是阿尔茨海默病。
• Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones
  作者：John E. Francis、William D. Cash、Beverly S. Barbaz、Patrick S. Bernard、Richard A. Lovell、Gerard C. Mazzenga、Robert C. Friedmann、James L. Hyun、Albert F. Braunwalder

  DOI：10.1021/jm00105a044

  日期：1991.1

  Investigation of tricyclic heterocycles related to the 2-arylpyrazolo[4,3-c]quinolin-3(5H)-ones, structures with high affinity for the benzodiazepine (BZ) receptor, led to the synthesis of 2-phenyl-[1,2,4]triazolo[1,5-c]quinazolin-5(6H)-one, a compound with 4 nM binding affinity to the BZ receptor. Analogues were prepared to assess the importance of the 2-substituent and ring substitution in modifying

  对与2-芳基吡唑并[4,3-c]喹啉-3（5H）-ones相关的三环杂环的研究，对苯二氮卓（BZ）受体具有高亲和力的结构导致了2-苯基-[1， 2,4] triazolo [1,5-c] quinazolin-5（6H）-one，一种对BZ受体具有4 nM结合亲和力的化合物。制备类似物以评估2-取代基和环取代在修饰活性中的重要性。设计了几种新颖的合成路线来制备目标化合物，包括从蒽腈和酰肼开始的两步合成。在该系列筛选的34种化合物中，在大鼠模型中发现3种化合物是有效的BZ拮抗剂。前导化合物9-氯-2-（2-氟苯基）[1,2,4]三唑并[1,5-c]喹唑啉-5（6H）-一（CGS 16228），
• Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives
  申请人：Knust Henner

  公开号：US20060084801A1

  公开（公告）日：2006-04-20

  The invention relates to halogen substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of formula I wherein R 1 , R 2 , R 3 , R 4 and n are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The compounds can be used as a cognitive enhancer or for the treatment of cognitive disorders, anxiety, Alzheimer's disease and schizophrenia.

  该发明涉及公式I中卤代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮平衍生物，其中R1、R2、R3、R4和n如规范中定义，并且其药学上可接受的酸盐。这些化合物可用作认知增强剂或用于治疗认知障碍、焦虑、阿尔茨海默病和精神分裂症。
• Synthesis and Evaluation of Adenosine Antagonist Activity of a Series of [1,2,4]Triazolo[1,5-c]quinazolines
  作者：Carmen Balo、Carmen López、José Manuel Brea、Franco Fernánde、Olga Caamaño

  DOI：10.1248/cpb.55.372

  日期：——

  series of [1,2,4]triazolo[1,5-c]quinazolines were prepared in satisfactory yields by reaction of some derivatives of 2-aminobenzohydrazide with several hydrochlorides of aromatic amidines, and their binding affinities for the recombinant human adenosine A2A and A2B receptors were determined. None of the new compounds showed noteworthy affinity for these receptors, though a very high affinity for the A2A

  通过2-氨基苯甲酰肼的某些衍生物与几种芳香族hydro盐酸盐的反应及其对重组人腺苷A2A的结合亲和力，以令人满意的收率制备了一系列[1,2,4]三唑并[1,5-c]喹唑啉确定了A2B受体。新化合物均未显示出对这些受体的显着亲和力，尽管对A2A受体的亲和力非常高，因此对其中一种合成的化合物显示出很高的A2A / A2B选择性。